Cancer Research Institute, Inc.
June 30, 2011
The Cancer Research Institute by wisely selecting and generously supporting investigators and projects on cancer research has immensely contributed to advance our understanding of malignancies, thus paving the way for novel therapies. With the support of the CRI we have developed new MHC-peptide based reagents that allow improved detection and isolation of antigen-specific CD8+ and CD8+ T lymphocytes. We endeavour after final optimization to make these reagents generally available, thus contributing to better monitor and understand cancer specific T cell immunity.
I've personally experienced the results of this organization in...
The support of the CRI was critical for our efforts, which without it may have afiled.
Ways to make it better...
If I had to make changes to this organization, I would...
The programs seem well balanced. In terms of comparing and validating diagnostic and monitoring tools wider and more stringent comparisons might be useful.
Professional with expertise in this field & I helped to develope new reagents for monitoring anti-cancer immunity.